Today NovaSight, an Israeli digital eye treatment and assessment startup in the pediatric space, announced a clinical trial for its CureSight system, with the goal of achieving Food and Drug Administration 510(k) clearance.
CureSight presents a new treatment method for amblyopia, also known as lazy eye, that doesn’t require patching. The device trains the brain to use both eyes simultaneously...
Israel-based startup specialising in AI vision care, NovaSight, has announced that it has finalised its round A financing totalling $8 million.
The round was led by venture capital firm, Rimonci Capital and joined by strategic investors from both pharmaceutical and medical device industries.
Prior to this round, the company raised $8 million for a total of $16 million.
WHY IT MATTERS
The funds...
